Ann: Incannex to Acquire APIRx Pharmaceuticals, page-82

We just went ex-entitlement. So that's 2c off. That puts us roughly at zero for the day.

Not surprising that the "acquisition" (closer to a merger, as it's all scrip) is fairly level. There's no way for us to price it. Is US$93m a great price or a terrible one? End of the day, it gives us a few more avenues, but we already had a lot of avenues, and funding them was already a stretch. So there's difficulties associated as well.

Nothing wrong with the market today. It just hasn't figured out a roadmap yet.